Nausea and Vomiting, Chemotherapy-Induced Clinical Trial
Official title:
A Phase I, Randomized, Double-Blind Study to Assess the Effects of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of Repeat Oral Dosing of Casopitant in Healthy Subjects
Verified date | August 2017 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Casopitant may affect liver enzymes that metabolize ketoconazole. This study is designed to test the safety and the extent of the Casopitant affect on ketoconazole levels in healthy human subjects.
Status | Completed |
Enrollment | 85 |
Est. completion date | August 27, 2007 |
Est. primary completion date | August 27, 2007 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion criteria: - A female subject who is non-childbearing potential or using acceptable contraceptive methods. - Adequate organ system functions. - Able to swallow and retain oral medication. - Subject is able to understand and comply with protocol requirements and instruction and is likely to complete the study. Exclusion Criteria: - Current clinically relevant abnormality, medical condition, or circumstance that makes the subject unsuitable for the study per the study doctor. - History of drug or other allergy which, in the opinion of the study doctor, contraindicates participation. - Use of an investigational drug within 28 days or 5 half-lives. - Use of prescription or non-prescription drugs, supplements or vitamins (excluding multivitamins) within 14 days, or 5 half-lives prior to first dose of study medication. - Blood donation in excess of 500mL within 56 days prior to dosing or intends to donate within 30 days of the post-treatment follow-up visit. - Iron deficiency. - Positive stool for occult blood. - Female subject who is pregnant or lactating. - Male subject who has a history of hypogonadism. - Positive urine drug screen. - Positive for HIV antibody, hepatitis C antibody or hepatitis B surface antigen. - Use of tobacco-containing products within the past 12 months prior to screening. - History of drug or alcohol abuse or dependence within 6 months of screening. - History or presence of uncontrolled emesis. - Presence of active infection. - History of cholecystectomy or biliary tract disease. - Active peptic ulcer disease (PUD) or a history of PUD of unknown etiology. - Any degree of heart failure. - Consumption of any food or drink containing grapefruit or grapefruit juice, apple juice, Seville oranges, kumquats, pommelos or vegetables from the mustard green family within 7 days prior to the first dose unless prior approval is received. |
Country | Name | City | State |
---|---|---|---|
United States | GSK Investigational Site | Buffalo | New York |
United States | GSK Investigational Site | Columbus | Ohio |
United States | GSK Investigational Site | Overland Park | Kansas |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
United States,
Johnson BM, Adams LM, Zhang K, Gainer SD, Kirby LC, Blum RA, Apseloff G, Morrison RA, Schutz RA, Lebowitz PF. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. J Clin Pharmacol. 2010 Aug;50(8):951-9. doi: 10.1177/0091270009353761. Epub 2010 Feb 2. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plasma levels of casopitant and ketoconazole will be checked on Day 4 to 9 in Cohort 1. | Day 4 to 9 in Cohort 1. | ||
Primary | Plasma levels of casopitant will be checked on Day 2 to 4 of Period 1 and | Day 2 to 4 of Period 1 | ||
Primary | casopitant and ketoconazole will be checked on Day 4 to 9 of Period 2. | Day 4 to 9 of Period 2 | ||
Secondary | Safety is evaluated in Cohort 1 by: - Clinical Lab Tests & Physical Exam at Screen, Day -1 & Followup (FU) | at Screen, Day -1 & Followup (FU) | ||
Secondary | - Vitals Signs monitored at Screen, Day -1, 4-7 and FU | at Screen, Day -1, 4-7 and FU | ||
Secondary | - 12 lead ECGs at Screen & FU | at Screen & FU | ||
Secondary | - Adverse Events Monitoring starting at Day 1 | Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00404378 -
Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]
|
Phase 1 | |
Completed |
NCT00431236 -
A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
|
Phase 3 | |
Completed |
NCT00405080 -
A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).
|
Phase 1 | |
Completed |
NCT00404274 -
A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers
|
Phase 1 | |
Completed |
NCT00440128 -
The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer
|
Phase 1 | |
Completed |
NCT00601172 -
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
|
Phase 3 | |
Completed |
NCT00511823 -
The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects
|
Phase 1 | |
Completed |
NCT00366834 -
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
|
Phase 3 | |
Completed |
NCT00437229 -
A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults
|
Phase 1 | |
Completed |
NCT00104403 -
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy
|
Phase 2 | |
Completed |
NCT01449188 -
To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects
|
Phase 1 | |
Terminated |
NCT00334646 -
Cyclophosphamide Drug Interaction Study In Cancer Patients
|
Phase 1 |